Skip to main content

Table 2 Ingenuity pathway analysis BioProfiler results showing genes significantly differentially expressed by sex in TARGET-OS that have existing chemotherapies for other cancers

From: Sex differences in expression of immune elements emerge in children, young adults and mice with osteosarcoma

Gene Molecule Type Higher gene expression Differential gene expression, p value Cancers known to be associated with the gene Drug trials for particular condition associated with this gene
ACHE Enzyme Males 0.005 Brain tumor, leukemia, lung cancer Phase 3
C3 Peptidase Females 0.01 Neuroblastoma, Langerhans cell histiocytosis, leukemia Approved, phase 2/3, phase 3
CD3D Transmembrane receptor Females 0.006 B cell acute lymphoblastic lymphoma, lymphoblastic B cell lymphoma Approved, phase 2/3, phase 3
CD3E Transmembrane receptor Females 0.009 B cell acute lymphoblastic lymphoma, B cell acute lymphoblastic leukemia Approved, phase 2/3, phase 3
CDK4 Kinase Females 0.02 Breast cancer, soft tissue sarcoma, lung cancer, melanoma Approved, phase 2/3, phase 3, phase 4
CEACAM5 Other Females 0.04 Lung cancer Phase 3
CHRNA7 Transmembrane receptor Males 0.03 Bladder cancer Phase 4
CYP19A1 Enzyme Females 0.02 Breast cancer, fallopian tube neoplasm, ovarian carcinoma, serous peritoneal adenocarcinoma, leiomyoma, uterine cancer Approved, phase 2/3, phase 3, phase 4
FCGR3A/FCGR3B Transmembrane receptor Females 0.009 Neuroblastoma, Langerhans cell histiocytosis, leukemia Approved, phase 2/3, phase 3
FLT3 Kinase Females 0.03 Chronic myelogenous leukemia, acute myeloid leukemia, acute myeloid leukemia associated with myelodysplastic syndrome, non-small cell lung cancer, colorectal adenocarcinoma, hepatocellular carcinoma, renal cell carcinoma, advanced stage gastrointestinal stromal tumor, pancreatic neuroendocrine tumor Approved, phase 2/3, phase 3, phase 4
FSHR G-protein coupled receptor Females 0.04 Prostate cancer Phase 3
HTR3B Ion channel Females 0.03 Pancreatic cancer Phase 2/3
ICOS Transmembrane receptor Females 0.008 Head and neck cancers Phase 3
IL5 Cytokine Females 0.04 Nasal polyp Phase 3
KCNC1 Ion channel Males 0.0003 Prostate cancer Phase 4
KCND2 Ion channel Females 0.01 Prostate cancer Phase 4
LCK Kinase Females 0.04 Chronic myelogenous leukemia, acute lymphoblastic leukemia, angiosarcoma, non-small cell lung carcinoma, renal cell carcinoma, soft tissue sarcoma, epithelioid malignant pleural mesothelioma, extraskeletal osteosarcoma, leiomyosarcoma, colorectal adenocarcinoma, sarcoma, malignant peripheral nerve sheath tumor, malignant soft tissue neoplasm, cancer, chondrosarcoma, ovarian cancer, colorectal adenocarcinoma, soft tissue sarcoma, melanoma, synovial sarcoma Approved, phase 2/3, phase 3, phase 4
MUC16 Other Females 0.03 Ovarian cancer Phase 3
PLA2G2A Enzyme Females 0.03 Advanced oral squamous cell carcinoma, colorectal cancer, Langerhans cell histiocytosis, primary oral squamous cell carcinoma, soft palate squamous cell carcinoma Phase 2/3, phase 3, phase 4
ROS1 Kinase Females 0.03 Lung cancer, hepatocellular carcinoma, renal cell carcinoma, soft tissue sarcoma, T cell lymphoma, myofibroblastic tumor, neuroblastoma, gastrointestinal carcinoid tumor, neuroendocrine malignant tumor, pancreatic endocrine tumor, thyroid cancer, pancreatic neuroendocrine tumor, melanoma Approved, phase 2/3, phase 3, phase 4
TGFB2 Growth factor Males 0.04 Anaplastic astrocytoma, glioblastoma Phase 3
TNFRSF8 Transmembrane receptor Males 0.001 Hodgkin lymphoma, T cell lymphoma, anaplastic large cell lymphoma Approved, phase 3, phase 4
TP53 Transcription regulator Females 0.0002 Myelodysplastic syndrome Phase 3
TUBB4A Other Males 0.02 Anaplastic glioma, anaplastic oligodendroglioma, glioma, B cell-like diffuse large B cell lymphoma, acute lymphoblastic leukemia, lymphoma, acute myeloid leukemia, non-small cell lung cancer, ovarian cancer, d breast cancer, cervical cancer, cholangiocarcinoma, endometrial carcinoma, esophageal cancer, fallopian tube cancer, follicular B cell or T cell lymphoma, gastric adenocarcinoma, pancreatic cancer, prostate cancer, sarcoma, soft tissue sarcoma, testicular carcinoma, bladder carcinoma, AIDS-related Kaposi sarcoma, anaplastic astrocytoma, anaplastic medulloblastoma, angiosarcoma Approved, phase 2/3, phase 3, phase 4